NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. INP Team 9 participated in a joint review on Tau molecular structures
  2. New article of the cytoskeleton and neurophysiopathology team

    The last work of team 9 "Tau regulates the microtubule-dependent migration of glioblastoma cells via Rho-ROCK signaling pathway" is now published in J. cell. Science. This work identifies for the first time the role and mechanisms implicating the tau protein in the invasion processes of glioblastomas, very aggressive brain tumors. This work highlights the role of the Tau protein as a common target between cancers and neurodegeneration.

  3. Hervé Kovacic elected president of the CNU section 85

    Professor of Biophysics and Biomathematics at the Faculty of Pharmacy of Marseille, Hervé Kovacic is elected for a six-year term. Section CNU 85 manages the qualifications, promotions and bonuses of teacher-researchers specializing in physicochemical sciences and applied engineering in health. Doctor Pascale Barbier, also from team 9 of INP has been nominated as a member of the same CNU section.

  4. Jean-Michel Paumier successfully defended his doctoral thesis

    Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.

  5. 3 PhD students of the INP participate in the Neuroschool PhD Days 2018

    On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students  were invited to present their work.

    It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.

  6. Vect-Horus announces agreement with Johnson & Johnson innovation

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.

  7. Santiago Rivera gave two conferences on Alzheimer's disease

    The first conference entitled “Alzheimer’s disease, fears and hopes” was given at the meeting of the management boards of the french Vaincre l’Alzheimer and the german Alzheimer Forschung Initiative foundations that was held on November 16th 2018 at the Novotel Hotel Marseille Vieux Port.

    The second conference, in the context of the Conferences Cycle of the Institute of Neurosciences of the University of Barcelona, was entitled “ Membrane type-matrix metalloproteinases are newcomers to the Alzheimer’s field ”  ans was held on November 20th at the School of Pharmacy of the University of Barcelona.

  8. New article from the Neural Degeneration and Plasticity team

    The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R). Our data unveil new mechanistic insights supporting the pro-amyloidogenic role of MT1-MMP based on APP processing and trafficking, and reinforces the idea that MT1-MMP may become a new potential therapeutic target in Alzheimer’s disease. 

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

New article from the Neural Degeneration and Plasticity team

The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R).

Undefined

Yvon Berland and Alexandre Tokay, respectively President of AMU and CEO of Vect-Horus signed a Public-Private Partnership allowing Vect-Horus to settle its research activities in the La Timone Medical Faculty

Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.

Undefined

New article from the NeuroCyto Team: Slow axonal transport of actin via hotspots and trails

The latest work of the NeuroCyto Team (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab to reveal a new mechanism of slow axonal transport, based on the previous discovery of actin hotspots and trails. Hotspots are static actin clusters that appear and disappear within minutes every 3-4 µm along the axon.

Undefined
Details of hotspots seen by STORM

1st Congress of the 7 CoENs (International Network of Centers of Excellence in Neurodegeneration)

Santiago Rivera represented the INP on the 1st Congress of the 7 CoENs (International Neetwork of Centers of Excellence in Neurodegeneration) held in Montpellier on October 18 and 19, 2018, endorsed by AVIESAN: Bordeaux, Grenoble, Lille, Montpellier, Marseille, Paris and Toulouse. He gave a lecture in the CoEN Pathfinder laureates’ session entitled MT-MMPs at the crossroads of amyloidogenesis and neuroinflammation in Alzheimer's disease.

Undefined

Ludovic Leloup (team cytoskeleton & neurophysiopathology) received a 30 000 € grant from the GEFLUC

The Emergence project entitled “Tau, from Alzheimer disease to glioblastoma, evolution of a prognostic marker” was selected by the Canceropole PACA to be founded by the GEFLUC (groupement des entreprises françaises dans la lutte contre le cancer). Team 9 has a long-time expertise on Tau and this grant will be used to complete the identification of the kinases responsible for Tau phosphorylation in glioblastoma.

Photo from the GEFLUC

Undefined

NeuroSchool: a School of Neuroscience for and by AMU students

On September 12, over 300 students, teachers, researchers, clinicians and entrepreneurs participated in the launch of NeuroSchool, the school that unifies and harmonizes the teachings of the third year of the bachelor's degree (Neuroscience path), the master's degree and the PhD program in neuroscience. Funded by the National Research Agency and the A*Midex Foundation, NeuroSchool will benefit from a funding of approximately 10 million euros (over 10 years).

Undefined

Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED participated in the ECMED EU-GliaPhD international conference organized in Malta

Michel Khrestchatisky gave a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.       

Undefined

Partners